PYC Therapeutics Ltd
ASX:PYC
Balance Sheet
Balance Sheet Decomposition
PYC Therapeutics Ltd
PYC Therapeutics Ltd
Balance Sheet
PYC Therapeutics Ltd
| Jun-2004 | Jun-2005 | Jun-2006 | Jun-2007 | Jun-2008 | Jun-2009 | Jun-2010 | Jun-2011 | Jun-2012 | Jun-2013 | Jun-2014 | Jun-2015 | Jun-2016 | Jun-2017 | Jun-2018 | Jun-2019 | Jun-2020 | Jun-2021 | Jun-2022 | Jun-2023 | Jun-2024 | Jun-2025 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||||||||||||||||
| Cash & Cash Equivalents |
1
|
0
|
0
|
3
|
3
|
3
|
1
|
5
|
3
|
2
|
4
|
1
|
7
|
10
|
3
|
6
|
7
|
18
|
29
|
16
|
67
|
153
|
|
| Cash |
1
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Cash Equivalents |
0
|
0
|
0
|
3
|
3
|
3
|
1
|
5
|
3
|
2
|
4
|
1
|
7
|
10
|
3
|
6
|
7
|
18
|
29
|
16
|
67
|
153
|
|
| Short-Term Investments |
0
|
5
|
2
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
18
|
33
|
0
|
0
|
0
|
0
|
|
| Total Receivables |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
10
|
16
|
18
|
24
|
|
| Accounts Receivables |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Receivables |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
10
|
16
|
18
|
24
|
|
| Other Current Assets |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
0
|
|
| Total Current Assets |
1
|
6
|
3
|
3
|
3
|
3
|
1
|
5
|
3
|
2
|
4
|
2
|
7
|
10
|
3
|
6
|
26
|
52
|
39
|
32
|
86
|
178
|
|
| PP&E Net |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
1
|
2
|
1
|
2
|
2
|
|
| PP&E Gross |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
1
|
2
|
1
|
2
|
2
|
|
| Accumulated Depreciation |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
1
|
1
|
1
|
1
|
0
|
0
|
1
|
2
|
2
|
3
|
3
|
4
|
5
|
|
| Intangible Assets |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
5
|
5
|
4
|
4
|
4
|
4
|
|
| Other Long-Term Assets |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Assets |
1
N/A
|
6
+421%
|
3
-54%
|
4
+25%
|
4
-1%
|
3
-1%
|
2
-55%
|
6
+261%
|
4
-38%
|
2
-35%
|
5
+100%
|
2
-60%
|
7
+307%
|
10
+42%
|
3
-67%
|
7
+96%
|
32
+371%
|
58
+84%
|
45
-22%
|
37
-18%
|
91
+145%
|
183
+101%
|
|
| Liabilities | |||||||||||||||||||||||
| Accounts Payable |
0
|
0
|
0
|
1
|
0
|
0
|
1
|
1
|
0
|
1
|
0
|
0
|
1
|
1
|
2
|
0
|
0
|
2
|
3
|
5
|
8
|
9
|
|
| Accrued Liabilities |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
1
|
3
|
1
|
3
|
|
| Short-Term Debt |
1
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Current Portion of Long-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Current Liabilities |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
|
| Total Current Liabilities |
1
|
0
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
2
|
0
|
1
|
3
|
4
|
8
|
9
|
12
|
|
| Long-Term Debt |
0
|
0
|
0
|
0
|
0
|
1
|
1
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
1
|
1
|
0
|
1
|
1
|
|
| Minority Interest |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
2
|
1
|
1
|
1
|
1
|
0
|
|
| Other Liabilities |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Liabilities |
1
N/A
|
0
-51%
|
1
+132%
|
1
+86%
|
1
-39%
|
2
+93%
|
2
+27%
|
1
-35%
|
1
-39%
|
1
+34%
|
1
-24%
|
1
+2%
|
1
+74%
|
1
+4%
|
2
+19%
|
0
-77%
|
4
+794%
|
5
+36%
|
6
+23%
|
9
+57%
|
11
+14%
|
14
+28%
|
|
| Equity | |||||||||||||||||||||||
| Common Stock |
1
|
8
|
8
|
12
|
17
|
20
|
22
|
30
|
32
|
34
|
40
|
40
|
48
|
53
|
53
|
62
|
87
|
126
|
126
|
140
|
231
|
370
|
|
| Retained Earnings |
0
|
2
|
6
|
10
|
14
|
18
|
22
|
26
|
30
|
33
|
36
|
39
|
43
|
44
|
52
|
56
|
59
|
73
|
87
|
112
|
150
|
200
|
|
| Total Equity |
1
N/A
|
6
+951%
|
2
-63%
|
2
+4%
|
3
+23%
|
2
-29%
|
0
N/A
|
4
N/A
|
3
-38%
|
1
-56%
|
4
+213%
|
1
-74%
|
6
+506%
|
9
+52%
|
2
-81%
|
6
+282%
|
28
+344%
|
53
+90%
|
39
-26%
|
28
-29%
|
80
+190%
|
170
+111%
|
|
| Total Liabilities & Equity |
1
N/A
|
6
+421%
|
3
-54%
|
4
+25%
|
4
-1%
|
3
-1%
|
2
-55%
|
6
+261%
|
4
-38%
|
2
-35%
|
5
+100%
|
2
-60%
|
7
+307%
|
10
+42%
|
3
-67%
|
7
+96%
|
32
+371%
|
58
+84%
|
45
-22%
|
37
-18%
|
91
+145%
|
183
+101%
|
|
| Shares Outstanding | |||||||||||||||||||||||
| Common Shares Outstanding |
57
|
140
|
141
|
160
|
186
|
280
|
306
|
520
|
599
|
599
|
1 226
|
1 226
|
2 058
|
2 177
|
2 196
|
2 508
|
2 953
|
3 181
|
324
|
348
|
475
|
586
|
|